ArticlePLoS medicine2021
An open science pathway for drug marketing authorization-Registered drug approval.
Article in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.JAMA network open · 2022Pooled it
- Quantitative analysis of new drug registration policies for traditional Chinese medicine using the PMC index model.Frontiers in public health · 2025Article
- Research on the impact of traditional Chinese medicine registration innovation-oriented policies and enterprises performance: an empirical analysis based on listed enterprises in China.Frontiers in public health · 2025Article
- Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.BMJ evidence-based medicine · 2024Article
- Enriching single-arm clinical trials with external controls: possibilities and pitfalls.Blood advances · 2023Article
- Integrating open science education into an undergraduate health professional research program.Journal of the Medical Library Association : JMLA · 2022Article
- A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.International journal of health services : planning, administration, evaluation · 2022Article
- Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment Reports.BMC medicine · 2022Article
- A network of change: united action on research integrity.BMC research notes · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Florian Naudet and co-authors propose a pathway involving registered criteria for evaluation and approval of new drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.